PARP1 and ovarian cancer: Germline BRCA mutated ovarian cancers have a distinct clinical behaviour characterized by younger age at diagnosis, visceral extent of the disease, higher response rates specifically to platinum chemotherapeutic agents, and sensitivity to PARP inhibitors [11].